Needham Upgrades TransMedics Group (TMDX) to Buy

Needham analyst Mike Matson upgraded TransMedics Group (NASDAQ: TMDX) from Hold to Buy with a price target of $148.00.

The analyst comments "We are upgrading TMDX to Buy from Hold. Our transplant tracker now indicates that TMDX's US sales are likely to beat consensus in 3Q25 based on the latest SRTR data. Additionally, we expect TMDX's new heart and lung clinical trials and its international expansion to become increasing growth drivers during 2026. TMDX's margins are also increasing rapidly and we expect meaningful EPS upside. Competition remains a potential risk, but we believe that TMDX has a significant lead in a still significantly underpenetrated market."

For an analyst ratings summary and ratings history on TransMedics Group click here. For more ratings news on TransMedics Group click here.

Shares of TransMedics Group closed at $119.54 yesterday.

You May Also Be Interested In

• Stephens Upgrades Varonis Systems (VRNS) to Overweight
• The Trade Desk (TTD) Reiterated at Market Perform by Citizens Amid Bad News
• Goldman Sachs Starts Twilio (TWLO) at Buy